Health

Results: 5917-5928 of 9338

NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in the United States

UNION therapeutics announce results from the ADESOS Phase 2b study in atopic dermatitis confirming the potential of orismilast as a first-in-class safe and efficacious oral treatment

ACCESSWIRE associated0

GEN Announces Positive Phase 2 Clinical Trial Results for GN-037 Topical Cream in Patients With Mild to Moderate Plaque Psoriasis

Business Wire logo

LivaNova to Announce Third-Quarter 2024 Results

PR Newswire associated0

Rx-360 Announces Approval as a Pilot Center of Excellence for the APEC Regulatory Harmonization Steering Committee

Business Wire logo

Perosphere Technologies to Deliver Oral Presentation & Posters on Point-of-Care Coagulometer at ADLM International CPOCT Symposium

Business Wire logo

Fujirebio Submits FDA Regulatory Filing for Lumipulse® G pTau 217/β-Amyloid 1-42 Plasma Ratio In-Vitro Diagnostic Test as an Aid to Identify Patients With Amyloid Pathology Associated With Alzheimer’s Disease

Business Wire logo

Medidata Extends Its Commitment to the Patient Experience with the Launch of Patient Payments

PR Newswire associated0

Alkermes to Host Investor Event to Review Orexin Portfolio Strategy

Business Wire logo

Multiple Late-Breaking Data Presentations from Incyte’s Dermatology Portfolio will be Featured at the European Academy of Dermatology and Venereology (EADV) 2024 Congress

PR Newswire associated0

OrbusNeich Launches a High-Capacity Logistics Center in the Netherlands

Almirall will be celebrating 80 years at the EADV 2024 (Graphic: Almirall)

New Data Show Almirall´s EBGLYSS® (Lebrikizumab) Provided Sustained Disease Control for up to Three Years in More Than 80% of Adults and Adolescents With Moderate-to-severe Atopic Dermatitis